產(chǎn)品目錄

規(guī)格	1mg 5mg 10mg 25mg
CAS	5300-03-8
別名	Alitretinoin
化學(xué)名	(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
分子式	C20H28O2
分子量	300.44
溶解度	≤0.5mg/ml in ethanol;20mg/ml in DMSO;20mg/ml in dimethyl formamide
儲存條件	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request

產(chǎn)品描述：

Ki: 0.5-27 nM for RAR; 3.8-12 nM for RXR

9-cis-Retinoic acid (9cRA) is a RAR and RXR activator.

Metabolism activates vitamin A into retinoic acid (RA), which controls physiological processes such as nervous system function, immune response, cell proliferation and differentiation, as well as reproduction. Much of the activity of RA is mediated via two subfamilies of nuclear receptors, retinoic acid receptor (RAR) and retinoid X receptor (RXR).

In vitro: The 9cRA effect in pancreatic β-cells line INS-1 832/13 led to a decreased expression of Mptn associated to a concomitant increase of miR-375. Moreover, in the breast cancer model, 9cRA showed different effect on both Mtpn and miR-375 expression. Moreover, in INS-1 832/13, 3T3-L1 pre-adipocytes and MCF-7 but not in MDA-MB-231, the effect of 9cRA on Mptn gene expression and its miR was under the control of RARs and RXRs receptors [1].

In vivo: A chemoprevention study was conducted to evaluate the activity of 9cRA as an inhibitor of prostate carcinogenesis in male Wistar-Unilever rats. Results showed that continuous dietary administration of 9cRA reduced cancer incidence in the dorsolateral + anterior prostate. Similarly, 9cRA with same doses reduced the incidence of cancer in all accessory sex glands. Moreover, chronic dietary administration of 9cRA induced no gross or organ-specific toxicity and did not suppress group mean body weight gain [2].

Clinical trial: The impact of 9cRA on quality of life of alitretinoin in severe chronic hand eczema has been evaluated. At baseline, most patients had CHE characterized as severe by PGA (83 %). At last visit, 48 % of patients had a PGA response of clear/almost clear. Mean improvement in DLQI scores at week 24 was 58 % and 70 %. The overall incidence of AEs was low and similar in both groups [3].

特別提醒：

1. 本產(chǎn)品僅供科研使用。請勿用于醫(yī)藥、臨床診斷或治療，食品及化妝品等用途。請勿存放于普通住宅區(qū)。

2. 為了您的安全和健康，請穿好實(shí)驗(yàn)服并佩戴一次性手套和口罩操作。

原創(chuàng)作者：上海莼試生物技術(shù)有限公司

在線咨詢

留言注意事項(xiàng)：

1.遵守中華人民共和國有關(guān)法律、法規(guī)，尊重網(wǎng)上道德，承擔(dān)一切因您的行為而直接或間接引起的法律責(zé)任。

2.請您真實(shí)的反映產(chǎn)品的情況,不要捏造、誣蔑、造謠。如對產(chǎn)品有任何疑問,也可以留言咨詢。

3.未經(jīng)本站同意，任何人不得利用本留言簿發(fā)布個(gè)人或團(tuán)體的具有廣告性質(zhì)的信息或類似言論。

您感興趣的產(chǎn)品*
您的單位*
聯(lián)系人*
聯(lián)系電話*
詳細(xì)地址*
常用郵箱*
請輸入您對我們的意見或建議*
驗(yàn)證碼*